Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Elias Jabbour, Van Morris, Hagop Kantarjian, Cameron C. Yin, Elizabeth Burton, Jorge Cortes

Blood (2012) 120 (16): 3382–3383.

https://doi.org/10.1182/blood-2012-04-424192

Published: 2012

Journal Articles

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

Alfonso Quintás-Cardama, MD, Hagop M Kantarjian, Rajyalakshmi Luthra, PhD, Susan o'Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, Stefan Faderl, MD, Marina Konopleva, M.D., Ph.D., William G. Wierda, MD, PhD, Elizabeth Burton, Jorge E. Cortes

Blood (2011) 118 (21): 454.

https://doi.org/10.1182/blood.V118.21.454.454

Published: 2011

Journal Articles

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy,

Naveen Pemmaraju, MD, Hagop M. Kantarjian, Maria F Tanaka, Susan O'Brien, MD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Gautam Borthakur, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Elizabeth Burton, Brenda Walker, RN, Jorge E. Cortes

Blood (2011) 118 (21): 3771.

https://doi.org/10.1182/blood.V118.21.3771.3771

Published: 2011

Journal Articles

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

Elizabeth Burton, Ph.D., Bernice Wong, Jiazhong Zhang, Ph.D., Brian West, Ph.D., Gideon Bollag, Ph.D., Gaston Habets, Ph.D., Allison Galanis, Hoa Nguyen, Omotayo Arowojolu, Trivikram Rajhowa, Mark J. Levis, MD, PhD

Blood (2011) 118 (21): 3632.

https://doi.org/10.1182/blood.V118.21.3632.3632

Published: 2011

Journal Articles

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, Rajyalakshmi Luthra, PhD, Susan O'Brien, MD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Gautam Borthakur, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Elizabeth Burton, Brenda Walker, RN, Jorge E. Cortes

Blood (2011) 118 (21): 1700.

https://doi.org/10.1182/blood.V118.21.1700.1700

Published: 2011

Journal Articles

Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).

Alireza Eghtedar, MD, Hagop Kantarjian, MD, Elias Jabbour, MD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Elizabeth Burton, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 3442.

https://doi.org/10.1182/blood.V116.21.3442.3442

Published: 2010

Journal Articles

Characteristics and Outcome of Patients (pts) with V299L BCR-ABL Kinase Domain (KD) Mutation After Therapy with Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Dan Jones, MD, PhD, Yin Cameron, MD, PhD, Elizabeth Burton, Jorge Cortes, MD

Blood (2010) 116 (21): 3428.

https://doi.org/10.1182/blood.V116.21.3428.3428

Published: 2010

Journal Articles

Characteristics and Outcome of Chronic Myeloid Leukemia (CML) Patients with E255K and E255V BCR-ABL Kinase Domain Mutations.

Kiran Naqvi, MD, Hagop Kantarjian, MD, Alfonso Quintás-Cardama, MD, Elias Jabbour, MD, Susan O'Brien, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Elizabeth Burton, Jorge E. Cortes, MD

Blood (2010) 116 (21): 1226.

https://doi.org/10.1182/blood.V116.21.1226.1226

Published: 2010

Journal Articles

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Ali M Al-Ameri, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Elizabeth Burton, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Xavier Badoux, MD, Susan O'Brien, Gloria Mattiuzzi, MD

Blood (2010) 116 (21): 1233.

https://doi.org/10.1182/blood.V116.21.1233.1233

Published: 2010

Journal Articles

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2 nd and 3 rd Tyrosine Kinase Inhibitors (TKIs)

Liunan Li, MD, Hagop Kantarjian, MD, Meng Zhao, MD, Susan O'Brien, MD, Elias Jabbour, MD, Alfonso Quintás-Cardama, MD, Elizabeth Burton, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 1238.

https://doi.org/10.1182/blood.V116.21.1238.1238

Published: 2010

Journal Articles

Is There a Clinical Benefit for Less Than a Complete Cytogenetic Response (CCyR) for Patients (Pts) with Chornic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKI) as Second or Third Line Therapy?

Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Elizabeth Burton, Susan O'Brien, Srdan Verstovsek, MD, PhD, Marina Konopleva, MD, PhD, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Farhad Ravandi, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 1241.

https://doi.org/10.1182/blood.V116.21.1241.1241

Published: 2010

Journal Articles

Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib.

Ali M Al -Ameri, MD, Hagop Kantarjian, MD, Elizabeth Burton, Susan O'Brien, MD, Farhad Ravandi, M.D., Gautam Borthakur, MD, Brenda Walker, Mary Bath Rios, Jorge Cortes, MD

Blood (2009) 114 (22): 3291.

https://doi.org/10.1182/blood.V114.22.3291.3291

Published: 2009

Journal Articles

Phase I Study of Bendamustine in Refractory Leukemia.

Mary Beth Rios, RN, Elias Jabbour, MD, Farhad Ravandi, M.D., Tapan Kadia, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Elizabeth Burton, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4156.

https://doi.org/10.1182/blood.V114.22.4156.4156

Published: 2009

Journal Articles

Clinical Characteristics and Outcome of Patients (pts) with V299L BCRABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, Hagop M. Kantarjian, Dan Jones, MD, PhD, Elizabeth Burton, Jorge Cortes

Blood (2008) 112 (11): 1105.

https://doi.org/10.1182/blood.V112.11.1105.1105

Published: 2008

Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.

Blood (2008) 112 (11): 2126.

https://doi.org/10.1182/blood.V112.11.2126.2126

Published: 2008

NARROW

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy,

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).

Characteristics and Outcome of Patients (pts) with V299L BCR-ABL Kinase Domain (KD) Mutation After Therapy with Tyrosine Kinase Inhibitors (TKIs).

Characteristics and Outcome of Chronic Myeloid Leukemia (CML) Patients with E255K and E255V BCR-ABL Kinase Domain Mutations.

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2 nd and 3 rd Tyrosine Kinase Inhibitors (TKIs)

Is There a Clinical Benefit for Less Than a Complete Cytogenetic Response (CCyR) for Patients (Pts) with Chornic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKI) as Second or Third Line Therapy?

Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib.

Phase I Study of Bendamustine in Refractory Leukemia.

Clinical Characteristics and Outcome of Patients (pts) with V299L BCRABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only